This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
ObjectivesRegistered, prospective, multicenter study of the short-term clinical outcomes of a novel transcatheter aorticvalve system (Xcor system, Saint Medical Technology, Inc., Procedural, in-hospital, and follow-up clinical outcomes were evaluated after procedures.ResultsThe average age of the 130 patients was 71.24.4
Background Cardiogenic shock (CS) induced by severe aorticstenosis (AS) is a life-threatening condition with high mortality. In-hospital mortality pooled estimated rates were 11% for eTAVI (CI 0.06 - 0.18) and for eBAV 40% (CI 0.28 - 0.54). Methods A systematic literature review and meta-analysis was performed.
Getty Images milla1cf Mon, 01/29/2024 - 14:24 January 29, 2024 — Despite national guidelines recommending surgical aorticvalve replacement (SAVR) for patients under age 65 with severe aorticstenosis , many hospitals are still opting for a nonsurgical approach in patients under 60—possibly with poorer survival rates.
Data shows, versus surgery, the Evolut transcatheter aorticvalve replacement (TAVR) system delivers a numerically lower rate of all-cause mortality or disabling stroke at five years, strong valve performance and durable clinical outcomes. Reardon, M.D.,
A normal functioning aorticvalve has three leaflets, usually referred to as cusps, and is positioned at the end of the left ventricle. This valve is the main pump that delivers oxygenated blood to the entire body. Today we take a deep dive into aorticvalve replacement, so you can have the knowledge you need.
Morristown Medical Center’s Gagnon Cardiovascular Institute’s structural heart program recently reported it has reached a significant milestone of performing over 5,000 transcatheter aorticvalve replacement (TAVR) procedures, the first in New Jersey and among the first to accomplish this in the United States.
ResultsThe overall in-hospital mortality was 1,7%. There were no statistically significant differences in terms of stroke, paravalvular leak, mechanical ventilation time, blood transfusion requirements, pacemaker implantation, reexploration for bleeding, conversion, wound infection, or in-hospital stay.
Patient selection was based on the presence of isolated aorticvalve disease without the need for ascending aorta replacement or aortic root enlargement. The majority of patients (77.1%) presented with aorticstenosis, often accompanied by severe calcification. years, with 22.9% being female.
Presentation title: QUALITY OF LIFE ASSESSMENT AT 30-DAYS FOLLOW-UP OF THE VALVOSOFT PIVOTAL STUDY ON SEVERE AORTICVALVE STENOSE PATIENTS" (control number 16930) Time and date: April 8, 2024 - 9:32 a.m.–9:42 A summary of the poster session will be published on the Journal of the American College of Cardiology’s website.
BACKGROUND:Data concerning the outcomes of transcatheter aorticvalve replacement in type 0 bicuspid aorticstenosis (AS) are scarce. Self-expanding transcatheter heart valves were used in the majority of patients (n=1160; 91.4%). In the matched population, differences in mortality (30 days: 4.2% 2.44];P=0.035).
A nationwide observational analysis of patients with aorticstenosis (AS) and cardiogenic shock (CS) who underwent transcatheter aorticvalve replacement (TAVR) or surgical aorticvalve replacement (SAVR) determined that patients who underwent TAVR had lower in-hospital complications and resource utilization compared with SAVR.
BackgroundAortic stenosis (AS) in combination with left ventricular outflow tract obstruction (LVOTO) has occasionally been reported. Three months later, a transapical beating-heart septal myectomy (TA-BSM) was performed in our hospital.
BACKGROUND:Patients with paradoxical low-flow, low-gradient severe aorticstenosis exhibit low transvalvular flow rate (Q), while maintaining preserved left ventricular ejection fraction. Over a follow-up of up to 5 years, severe MR correlated with higher all-cause mortality (P=0.02) and aorticvalve replacement rates (P=0.012).
Transcatheter aorticvalve replacement (TAVR) is increasing in popularity for symptomatic severe aorticstenosis. Transfemoral arterial route is the most commonly used approach for TAVR, also known as TAVI or transcatheter aorticvalve implantation. No calcifications in the artery causing vascular stenosis.
BACKGROUND:This study aimed to compare the incidence and prognostic implications of new-onset conduction disturbances after surgical aorticvalve replacement (SAVR) in patients with bicuspid aorticvalve (BAV) aorticstenosis (AS) versus patients with tricuspid aorticvalve (TAV) AS (ie, BAV-AS and TAV-AS, respectively).
Objective The association between a combined anaemia and renal failure index and 1-year prognosis of patients undergoing transcatheter aorticvalve implantation (TAVI) is unexplored. Trial registration number 4143 (The Institutional Review Board of Kurashiki Central Hospital)
An 84-year-old woman was referred for transcatheter aorticvalve replacement (TAVR) following severe symptomatic aorticstenosis (valve area 0.9 cm2, peak and mean transaortic pressure gradients of 63 and 32 mmHg, respectively).
Objective To assess gender, ethnicity, and deprivation-based differences in provision of aorticvalve replacement (AVR) in England for adults with aorticstenosis (AS).
Background Aorticstenosis is a life-limiting condition for which transcatheter aorticvalve implantation (TAVI) is an established therapy. Objectives We sought to examine the association of coexistent CAD on mortality and hospital readmission in patients undergoing TAVI.
Objectives To understand the patient and hospital level drivers of the variation in surgical versus trascatheter aorticvalve replacement (SAVR vs TAVR) for patients with aorticstenosis (AS) and to explore whether this variation translates into differences in clinical outcomes.
BACKGROUND:The extent of cardiac damage has been shown to be associated with increased mortality, repeat hospitalization, and decreased quality of life after aorticvalve replacement (AVR). Patients were categorized into 5 groups (stages 04) based on their stage of cardiac damage in the year before AVR.
If you’ve been diagnosed with aorticstenosis, you might have come across the term TAVR. Understanding AorticStenosis The aorticvalve regulates blood flow from your heart’s main pumping chamber to the rest of your body. In aorticstenosis, the valve leaflets stiffen and narrow, restricting blood flow.
Background:The optimal treatment in patients with severe aorticstenosis (AS) and small aortic annulus (SAA) remains to be determined. Participants were 151 patients with severe AS and SAA (mean diameter <23 mm) were randomized (1:1) to TAVR (n=77) vs SAVR (n=74), The primary outcome was impaired valve hemodynamics (i.e.
Background:Peak aorticvalve Doppler velocity, mean aorticvalve gradient, and Doppler estimated aorticvalve area are key measures recommended for assessing aorticstenosis severity. Failure to accurately diagnose severe aorticstenosis is critical.
We know that structural heart disease and heart failure are the leading causes of hospitalization and morbidity in the U.S. Standalone performance for significant major valve disease pathology (aorticstenosis and regurgitation and mitral and tricuspid regurgitation) had a 93 percent sensitivity and 93 percent specificity.
Although low BP can be seen in those hospitalized with signs of shock, the most common scenario involves non-severe, asymptomatic hypotension in patients receiving foundational therapy for HFrEF, where premature down-titration or discontinuation of GDMT should be avoided.
A cost-effectiveness analysis demonstrates the positive economic value of transcatheter aorticvalve replacement (TAVR) using Evolut TAVR compared to surgical aorticvalve replacement (SAVR) for low-risk patients. At Medtronic, we continue to emphasize that valve design matters. mmHg TAVR; 11.8
It also allows for less blood loss, reduced pain, shorter hospital stays, and a lower chance of infection. AorticValve Replacement (AVR): AVR is a minimally invasive procedure in which the surgeon makes a small incision and allows the heart to continue to beat during the entire procedure.
The diagnostic coronary angiogram identified only minimal coronary artery disease, but there was a severely calcified, ‘immobile’ aorticvalve. Aortic angiogram did not reveal aortic dissection. If you see this, you should Doppler the valve. Patient was continued on maximal pressors, but remained hypotensive.
tim.hodson Wed, 03/12/2025 - 10:46 March 12, 2025 New research from Karl Landsteiner University of Health Sciences (KL Krems) in Austria provides important new insights into how aorticvalve size is associated with the degree of valve calcification in severe aorticstenosis (AS).
Among patients with asymptomatic severe aorticstenosis, early TAVR was superior to clinical surveillance in reducing the incidence of death, stroke, or unplanned hospitalization for cardiovascular causes.
Background Treatment of severe aorticstenosis with transcatheter aorticvalve implantation (TAVI) was introduced in 2002. Methods This retrospective observational study included 867 patients who underwent TAVI at the University Hospital of North Norway in Tromsø from 2008 to 2021.
BackgroundThe coexistence of transthyretin cardiac amyloidosis (ATTRCA) and aorticstenosis (AS) is increasingly recognized, but the clinical consequences are unclear. Ad hoc subanalyses were conducted in patients with aorticvalve replacement at first diagnosis (surrogate for severe AS). 95% CI, 1.11.4];P<0.0001)
The EARLY TAVR trial results demonstrate that early transcatheter aorticvalve implantation in patients with asymptomatic severe aorticstenosis is superior to clinical surveillance in significantly reducing the composite primary outcome of death, stroke, or unplanned hospitalization for cardiovascular causes.
Background Coronary artery disease (CAD) is a common finding in patients with severe aorticstenosis undergoing transcatheter aorticvalve replacement (TAVR). There was no significant association between the presence of a CTO and in-hospital or 30-day mortality. There was also no difference in long-term survival.
Sinai Hospital (New York, NY). We believe the tools, resources, and information shared at the meeting will provide the healthcare community with greater expertise to improve patient outcomes and also connect with their interventional cardiology colleagues,” said SCAI President George D.
This study aimed to confirm the prognostic value of a novel angiographic microvascular resistance (AMR) index in patients undergoing transcatheter aorticvalve replacement.Methods and ResultsWe prospectively included 335 patients with severe aorticstenosis who underwent transcatheter aorticvalve replacement at Fuwai Hospital.
Aims The majority of patients with severe aorticstenosis (AS) planned for transcatheter aorticvalve implantation (TAVI) are elective outpatients. Results The primary endpoint consists of days lost due to cardiovascular hospitalization and death of any cause within 180 days after the heart team’s decision.
TAVR and SAVR are procedures to replace a damaged aorticvalve that is not functioning properly. guidelines recommend TAVR, a catheter-based approach in which the new valve is threaded to the heart through a blood vessel in the groin or chest, over open-heart SAVR for older patients and those with high cardiovascular risk. “We
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
52 
Let's personalize your content